Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab (MSB0010841) in moderate to severe psoriasis
NCT02156466Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2014
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sonelokimab in plaque psoriasis (5 arms), sponsored by Merck KGaA. Primary endpoints: Treatment Emergent Adverse Events at Day 85, Injection Site Reactions at Day 43 and 4 more. Started Aug 2014; status: completed.
02
Drugs
sonelokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02156466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156466.